Ubs Asset Management Americas Inc Lowers stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Ubs Asset Management Americas Inc reduced its stake in Celgene Corporation by 2.75% during the most recent quarter end. The investment management company now holds a total of 5,612,832 shares of Celgene Corporation which is valued at $562.2 Million after selling 158,573 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on May 12, 2016.Celgene Corporation makes up approximately 0.67% of Ubs Asset Management Americas Inc’s portfolio.

Other Hedge Funds, Including , Wafra Investment Advisory Group Inc Ny boosted its stake in CELG in the latest quarter, The investment management firm added 35,373 additional shares and now holds a total of 205,702 shares of Celgene Corporation which is valued at $20.6 Million. Celgene Corporation makes up approx 2.33% of Wafra Investment Advisory Group Inc Ny’s portfolio.Diam Ltd. boosted its stake in CELG in the latest quarter, The investment management firm added 46,453 additional shares and now holds a total of 356,407 shares of Celgene Corporation which is valued at $35.7 Million. Celgene Corporation makes up approx 0.52% of Diam Ltd.’s portfolio.Duff Phelps Investment Management Co reduced its stake in CELG by selling 2,570 shares or 19.74% in the most recent quarter. The Hedge Fund company now holds 10,450 shares of CELG which is valued at $1 Million. Celgene Corporation makes up approx 0.02% of Duff Phelps Investment Management Co’s portfolio.

Celgene Corporation opened for trading at $100.12 and hit $102.41 on the upside on Friday, eventually ending the session at $101.46, with a gain of 1.52% or 1.52 points. The heightened volatility saw the trading volume jump to 37,10,192 shares. Company has a market cap of $78,591,017 M.

On the company’s financial health, Celgene Corporation reported $1.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.27. The company had revenue of $2511.60 million for the quarter, compared to analysts expectations of $2577.08 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .Citigroup Initiated Celgene Corporation on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $130.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.